B of A Securities analyst Dina Ramadane has maintained a Buy rating on Vera Therapeutics (NASDAQ: VERA) and raised the price target to $70 from $65. The adjustment reflects increased confidence in the company's outlook following a review of its current market position and operational progress.

Rating and Price Action

The firm's decision to upgrade the price target underscores a positive sentiment toward Vera Therapeutics' future performance. The new target of $70 represents an upward revision from the previous estimate of $65, signaling potential growth in shareholder value.

Analyst Consensus

The following table summarizes the revised rating details:

The revised target suggests that the stock has room to appreciate based on the company's fundamentals and strategic direction.

The U.S. Food and Drug Administration (FDA) on Tuesday granted accelerated approval to Vera Therapeutics Inc.'s Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Following the announcement, the company's stock climbed nearly 9%. The approval is based on the therapy's ability to reduce proteinuria, though long-term evidence demonstrating whether the treatment slows kidney function decline has not yet been established. Continued approval may depend on confirmation of clinical benefit in the ongoing ORIGIN 3 study.

The Biologics License Application (BLA) submission was supported by a prespecified interim analysis from the ongoing Phase 3 ORIGIN 3 trial involving the first 203 participants. Patients treated with Trutakna recorded a 46% reduction from baseline in urine protein-to-creatinine ratio (UPCR). Compared with placebo, the therapy delivered a statistically significant 42% reduction in proteinuria at 36 weeks.

ORIGIN 3 Trial and Future Plans

The ORIGIN 3 trial remains an ongoing study evaluating adults with IgA nephropathy. Participants receive either once-weekly 150 mg subcutaneous Trutakna injections administered at home or a placebo. The study continues in a blinded, placebo-controlled manner to assess changes in kidney function measured by estimated glomerular filtration rate (eGFR). Vera Therapeutics expects those results in the third quarter of 2026. Pending these results, the company plans to submit a supplemental Biologics License Application (sBLA) for full approval in the fourth quarter of 2026.

Competitive Landscape

Novartis AG remains a key competitor in the IgAN treatment space. In April 2025, the FDA granted accelerated approval to Novartis's Vanrafia (atrasentan) for the reduction of proteinuria in adults with IgAN. In February, Novartis shared final results from the Phase 3 ALIGN study, which supported a slowing decline in kidney function in adults with IgAN treated with Vanrafia. Following the trial data, Novartis plans to submit for traditional approval in 2026.

Key Trial Data for Trutakna

Vera Therapeutics shares were up 8.97% at $43.73 at the time of publication on Tuesday.